SAGE Therapeutics Inc (NASDAQ:SAGE) Expected to Post Quarterly Sales of $3.96 Million

Equities research analysts predict that SAGE Therapeutics Inc (NASDAQ:SAGE) will report $3.96 million in sales for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have made estimates for SAGE Therapeutics’ earnings. The highest sales estimate is $15.00 million and the lowest is $1.13 million. The firm is expected to announce its next earnings report on Tuesday, November 5th.

On average, analysts expect that SAGE Therapeutics will report full year sales of $16.73 million for the current fiscal year, with estimates ranging from $4.28 million to $30.47 million. For the next year, analysts forecast that the business will report sales of $101.00 million, with estimates ranging from $39.27 million to $220.12 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.32) by $0.04. The company had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.27 million. The business’s revenue for the quarter was down 99.0% on a year-over-year basis. During the same period last year, the company posted ($0.36) EPS.

Several analysts have weighed in on SAGE shares. BidaskClub raised SAGE Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 9th. William Blair reaffirmed a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. Raymond James reaffirmed a “market perform” rating on shares of SAGE Therapeutics in a report on Friday, April 26th. Finally, LADENBURG THALM/SH SH set a $220.00 price target on SAGE Therapeutics and gave the company a “buy” rating in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $200.27.

Shares of NASDAQ:SAGE traded down $0.44 on Monday, hitting $167.40. The company’s stock had a trading volume of 14,337 shares, compared to its average volume of 407,494. The company has a 50-day simple moving average of $172.70 and a 200 day simple moving average of $166.85. SAGE Therapeutics has a 1 year low of $79.88 and a 1 year high of $193.56. The company has a market capitalization of $8.64 billion, a PE ratio of -20.60 and a beta of 2.53. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.00 and a quick ratio of 16.00.

In other news, Director James M. Frates sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $160.58, for a total value of $1,284,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey M. Jonas sold 94,264 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $174.75, for a total value of $16,472,634.00. Following the completion of the transaction, the chief executive officer now owns 116,023 shares of the company’s stock, valued at approximately $20,275,019.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 186,925 shares of company stock worth $32,558,557. 4.60% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its stake in SAGE Therapeutics by 40.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 109,054 shares of the biopharmaceutical company’s stock valued at $10,441,000 after purchasing an additional 31,571 shares during the last quarter. Geode Capital Management LLC raised its position in SAGE Therapeutics by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 467,917 shares of the biopharmaceutical company’s stock worth $44,821,000 after acquiring an additional 32,033 shares in the last quarter. State of Alaska Department of Revenue raised its position in SAGE Therapeutics by 1.3% in the first quarter. State of Alaska Department of Revenue now owns 5,680 shares of the biopharmaceutical company’s stock worth $903,000 after acquiring an additional 75 shares in the last quarter. Oakbrook Investments LLC bought a new stake in SAGE Therapeutics in the first quarter worth about $207,000. Finally, Brinker Capital Inc. raised its position in SAGE Therapeutics by 84.5% in the first quarter. Brinker Capital Inc. now owns 6,771 shares of the biopharmaceutical company’s stock worth $1,077,000 after acquiring an additional 3,102 shares in the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Read More: Capital Gains

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.